Acrivon Therapeutics (NASDAQ:ACRV) PT Raised to $22.00

Acrivon Therapeutics (NASDAQ:ACRVFree Report) had its price target upped by HC Wainwright from $20.00 to $22.00 in a report released on Tuesday morning, Benzinga reports. The brokerage currently has a buy rating on the stock.

A number of other brokerages have also recently weighed in on ACRV. BMO Capital Markets lifted their price target on shares of Acrivon Therapeutics from $18.00 to $25.00 and gave the company an outperform rating in a research report on Friday, April 26th. LADENBURG THALM/SH SH cut shares of Acrivon Therapeutics from a buy rating to a neutral rating in a research report on Monday, April 29th. JMP Securities raised their price objective on Acrivon Therapeutics from $14.00 to $17.00 and gave the company a market outperform rating in a research report on Thursday, April 25th. Finally, Piper Sandler upped their target price on Acrivon Therapeutics from $26.00 to $30.00 and gave the stock an overweight rating in a research report on Thursday, April 25th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the company has an average rating of Moderate Buy and a consensus price target of $22.88.

Get Our Latest Stock Report on ACRV

Acrivon Therapeutics Stock Performance

Acrivon Therapeutics stock opened at $8.36 on Tuesday. The company has a market cap of $189.27 million, a price-to-earnings ratio of -3.06 and a beta of 1.24. Acrivon Therapeutics has a 1 year low of $3.19 and a 1 year high of $14.30. The firm has a 50 day moving average price of $7.66 and a 200 day moving average price of $5.62.

Acrivon Therapeutics (NASDAQ:ACRVGet Free Report) last issued its earnings results on Thursday, March 28th. The company reported ($0.86) earnings per share for the quarter, missing the consensus estimate of ($0.72) by ($0.14). Sell-side analysts predict that Acrivon Therapeutics will post -3.05 EPS for the current year.

Insider Buying and Selling at Acrivon Therapeutics

In other Acrivon Therapeutics news, major shareholder Perceptive Advisors Llc bought 2,353,000 shares of the business’s stock in a transaction on Thursday, April 11th. The shares were bought at an average cost of $8.50 per share, with a total value of $20,000,500.00. Following the transaction, the insider now directly owns 5,360,858 shares in the company, valued at approximately $45,567,293. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 7.30% of the stock is owned by insiders.

Institutional Investors Weigh In On Acrivon Therapeutics

A number of institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. increased its holdings in Acrivon Therapeutics by 6.6% in the first quarter. Vanguard Group Inc. now owns 507,185 shares of the company’s stock valued at $3,626,000 after buying an additional 31,208 shares during the last quarter. Exchange Traded Concepts LLC grew its position in shares of Acrivon Therapeutics by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 13,289 shares of the company’s stock worth $65,000 after acquiring an additional 3,370 shares in the last quarter. Finally, American International Group Inc. increased its holdings in shares of Acrivon Therapeutics by 39.2% in the 1st quarter. American International Group Inc. now owns 6,016 shares of the company’s stock valued at $43,000 after acquiring an additional 1,695 shares during the last quarter. Institutional investors and hedge funds own 71.62% of the company’s stock.

About Acrivon Therapeutics

(Get Free Report)

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.

See Also

Analyst Recommendations for Acrivon Therapeutics (NASDAQ:ACRV)

Receive News & Ratings for Acrivon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acrivon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.